Actelion seeks CFDA approval for Zavesca in ultra-rare Niemann-Pick Type C
HONG KONG – Swiss biopharmaceutical Actelion Ltd. is seeking regulatory approval in China for its Zavesca (miglustat) to treat Niemann-Pick Type C (NPC), a rare disease for which there is little information and no treatment available in the country.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter